TY - JOUR
T1 - Clinicopathological and prognostic significance of mitogen-activated protein kinases (MAPK) in breast cancers
AU - Ahmad, Dena A.J.
AU - Negm, Ola H.
AU - Alabdullah, M. Layth
AU - Mirza, Sameer
AU - Hamed, Mohamed R.
AU - Band, Vimla
AU - Green, Andrew R.
AU - Ellis, Ian O.
AU - Rakha, Emad A.
N1 - Publisher Copyright:
© 2016, The Author(s).
PY - 2016/10/1
Y1 - 2016/10/1
N2 - Background: Mitogen-activated protein kinases (MAPKs) are signalling transduction molecules that have different functions and diverse behaviour in cancer. In breast cancer, MAPK is related to oestrogen receptor (ER) and HER2. Methods: Protein expression of a large panel of MAPKs (JNK1/2, ERK, p38, C-JUN and ATF2 including phosphorylated forms) were assessed immunohistochemically in a large (n = 1400) and well-characterised breast cancer series prepared as tissue microarray. Moreover, reverse phase protein array was applied to quantify protein expression of MAPKs in six breast cancer cell lines with different phenotypes including HER2-transfected cells. Results: MAPKs expression was associated with clinicopathological variables characteristic of good prognosis. These associations were most significant in the whole series and in the ER+ subgroup compared to other BC classes. Most of MAPKs showed a positive association with ER, BCL2 and better outcome and were negatively associated with the proliferation marker Ki67 and p53. Association of MAPK with HER2 was mainly seen in the ER- subgroup. Reverse phase protein array confirmed immunohistochemistry results and revealed differential expression of MAPK proteins in ER+ and ER− cell lines. Conclusions: MAPKs are associated with good prognosis and their expression is mainly related to ER. Studying a large panel rather than individual biomarkers may provide improved understanding of the pathway.
AB - Background: Mitogen-activated protein kinases (MAPKs) are signalling transduction molecules that have different functions and diverse behaviour in cancer. In breast cancer, MAPK is related to oestrogen receptor (ER) and HER2. Methods: Protein expression of a large panel of MAPKs (JNK1/2, ERK, p38, C-JUN and ATF2 including phosphorylated forms) were assessed immunohistochemically in a large (n = 1400) and well-characterised breast cancer series prepared as tissue microarray. Moreover, reverse phase protein array was applied to quantify protein expression of MAPKs in six breast cancer cell lines with different phenotypes including HER2-transfected cells. Results: MAPKs expression was associated with clinicopathological variables characteristic of good prognosis. These associations were most significant in the whole series and in the ER+ subgroup compared to other BC classes. Most of MAPKs showed a positive association with ER, BCL2 and better outcome and were negatively associated with the proliferation marker Ki67 and p53. Association of MAPK with HER2 was mainly seen in the ER- subgroup. Reverse phase protein array confirmed immunohistochemistry results and revealed differential expression of MAPK proteins in ER+ and ER− cell lines. Conclusions: MAPKs are associated with good prognosis and their expression is mainly related to ER. Studying a large panel rather than individual biomarkers may provide improved understanding of the pathway.
KW - Breast cancer
KW - MAPK signalling pathways
KW - Reverse phase protein microarray (RPPA)
UR - http://www.scopus.com/inward/record.url?scp=84984916653&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84984916653&partnerID=8YFLogxK
U2 - 10.1007/s10549-016-3967-9
DO - 10.1007/s10549-016-3967-9
M3 - Article
C2 - 27592113
AN - SCOPUS:84984916653
SN - 0167-6806
VL - 159
SP - 457
EP - 467
JO - Breast Cancer Research and Treatment
JF - Breast Cancer Research and Treatment
IS - 3
ER -
